NCT06658197View on ClinicalTrials.gov

Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

850

Participants

Timeline

Start Date

February 2, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

June 1, 2027

Conditions
Stroke, IschemicStroke, AcuteThrombosis, BrainDrug Effect
Interventions
DRUG

Tenecteplase

Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy

DRUG

Alteplase

Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy

Trial Locations (1)

100000

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER